dsp-2230 dsp-2230 dsp-2230 is a selective small-molecule nav1.7 and nav1.8 voltage-gated sodium channel blocker which is under development by dainippon sumitomo pharma for the treatment of neuropathic pain. as of june 2014, it is in phase i/phase ii clinical trials. dsp-2230clinical dataroutes ofadministrationby mouthidentifiers iupac name (2s)-2-pyridin-2-yl]methyl]amino]propanamide cas number1233231-30-5 yuniilsy2d22fbkchemblchembl3545012chemical and physical dataformulac20h20f3n5o2molar mass419.408 g·mol−13d model (jsmol)interactive image smiles fc1=cc(oc2=cc=c(n=c3cn((c(n())=o)c))c(n3c4ccc4)=n2)=cc(f)=c1f inchi inchi=1s/c20h20f3n5o2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25h,2-4,9h2,1h3,(h2,24,29)/t10-/m1/s1key:hhxcjimpejsjtg-snvbaglbsa-n